Lixte Financial Statements From 2010 to 2024

LIXT Stock  USD 3.35  0.12  3.46%   
Lixte Biotechnology financial statements provide useful quarterly and yearly information to potential Lixte Biotechnology Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lixte Biotechnology financial statements helps investors assess Lixte Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lixte Biotechnology's valuation are summarized below:
Market Capitalization
7.8 M
Earnings Share
(2.66)
There are currently one hundred twenty fundamental ratios for Lixte Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Lixte Biotechnology's last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 4.3 M in 2024. Enterprise Value is likely to drop to about 283.8 K in 2024
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or Total Operating Expenses of 2.7 M, as well as many exotic indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0017 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Lixte Biotechnology Technical models . Check out the analysis of Lixte Biotechnology Correlation against competitors.

Lixte Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.2 M4.3 M2.3 M
Slightly volatile
Other Current Liabilities171.6 K313.9 K145.8 K
Slightly volatile
Total Current Liabilities290.7 K313.9 K271 K
Slightly volatile
Cash4.4 M4.2 M2.3 M
Slightly volatile
Cash And Short Term Investments4.4 M4.2 M2.3 M
Slightly volatile
Common Stock Shares Outstanding1.8 M1.9 M42.9 M
Slightly volatile
Liabilities And Stockholders Equity2.2 M4.3 M2.3 M
Slightly volatile
Other Stockholder Equity51.4 M49 M24.8 M
Slightly volatile
Total Liabilities290.7 K313.9 K271 K
Slightly volatile
Total Current Assets2.2 M4.2 M2.3 M
Slightly volatile
Common Stock2142253.3 K
Slightly volatile
Property Plant And Equipment Net109115188
Slightly volatile
Accounts Payable169.4 K156.8 K164.5 K
Slightly volatile
Other Current Assets54 K27.1 K72.4 K
Slightly volatile
Common Stock Total Equity4.2 MM1.3 M
Slightly volatile
Short and Long Term Debt Total80 K90 K98 K
Slightly volatile
Net Receivables12.3 K12.9 K82.8 K
Slightly volatile
Inventory58.1 K70.1 K60.3 K
Slightly volatile
Current Deferred Revenue81.5 K157.1 K66.6 K
Slightly volatile
Preferred Stock Total Equity3.2 MM2.8 M
Slightly volatile
Net Working Capital4.2 MM2.5 M
Slightly volatile
Deferred Long Term Liabilities1.8 K2.1 K2.2 K
Slightly volatile
Capital Stock2.8 M3.5 M3.5 M
Slightly volatile

Lixte Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses2.7 M5.1 M2.9 M
Slightly volatile
Total Operating Expenses2.7 M5.1 M2.9 M
Slightly volatile
Depreciation And Amortization12.2 K12.9 K56.2 K
Slightly volatile
Selling General Administrative1.8 M3.1 M1.8 M
Slightly volatile
Research DevelopmentM898.1 KM
Pretty Stable
Interest Income12.9 K20.5 K7.2 K
Slightly volatile

Lixte Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock5.4 M5.2 MM
Slightly volatile
Total Cash From Financing Activities2.5 M3.1 M2.7 M
Slightly volatile
End Period Cash Flow4.4 M4.2 M2.3 M
Slightly volatile
Begin Period Cash Flow5.6 M5.4 M2.1 M
Slightly volatile
Depreciation109115148
Slightly volatile
Stock Based Compensation858.4 K773.2 K843.2 K
Slightly volatile
Dividends Paid1.7 K1.8 K8.5 K
Slightly volatile
Other Cashflows From Investing Activities86.2 K93.7 K104.4 K
Slightly volatile
Change To Netincome1.2 M1.8 M1.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.3510.5211.4517
Slightly volatile
Dividend Yield0.00170.00160.0013
Slightly volatile
Average Payables125.9 K205.1 K166.9 K
Slightly volatile
Stock Based Compensation To Revenue2.22.472.6934
Slightly volatile
EV To Sales9.2510.411.3274
Slightly volatile
Sales General And Administrative To Revenue3.023.393.6966
Slightly volatile
Research And Ddevelopement To Revenue8.379.4110.2505
Slightly volatile
Cash Per Share2.372.19413.9059
Slightly volatile
Capex To Operating Cash Flow8.0E-44.0E-45.0E-4
Pretty Stable
Income Quality0.540.8440.6974
Very volatile
Net Debt To EBITDA0.510.82580.6419
Slightly volatile
Current Ratio14.1513.47948.9476
Slightly volatile
Graham Number12.0811.161219.9242
Slightly volatile
Average Receivables7.8 K8.3 K14.1 K
Slightly volatile
Revenue Per Share0.210.230.2518
Slightly volatile
Ebt Per Ebit1.160.99941.0766
Slightly volatile
Quick Ratio14.0613.3938.4916
Slightly volatile
Net Income Per E B T0.790.90.9657
Slightly volatile
Cash Ratio14.0613.3938.2949
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0171
Slightly volatile
Capital Expenditure Coverage Ratio1.4 K2.3 K2.4 K
Very volatile
Price Sales Ratio9.3510.5211.4517
Slightly volatile
Asset Turnover0.260.30.3272
Slightly volatile

Lixte Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.3 M4.5 M1.1 B
Slightly volatile

Lixte Fundamental Market Drivers

Cash And Short Term Investments4.2 M

Lixte Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Lixte Biotechnology Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lixte Biotechnology income statement, its balance sheet, and the statement of cash flows. Lixte Biotechnology investors use historical funamental indicators, such as Lixte Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may use each financial statement separately, they are all related. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lixte Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lixte Biotechnology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue157.1 K81.5 K
Total Revenue 0.00  0.00 
Cost Of Revenue 0.00  0.00 
Stock Based Compensation To Revenue 2.47  2.20 
Sales General And Administrative To Revenue 3.39  3.02 
Research And Ddevelopement To Revenue 9.41  8.37 
Capex To Revenue 0.00  0.00 
Revenue Per Share 0.23  0.21 
Ebit Per Revenue(11.91)(12.50)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:
Check out the analysis of Lixte Biotechnology Correlation against competitors.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Return On Assets
(0.64)
Return On Equity
(1.11)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.